Vaxart (OTCMKTS:VXRT) Posts Earnings Results, Hits Expectations

Vaxart (OTCMKTS:VXRT) posted its quarterly earnings data on Thursday. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.02, Zacks reports. Vaxart had a net margin of 14.51% and a return on equity of 75.49%. The company had revenue of $39.23 million for the quarter, compared to the consensus estimate of $50.50 million.

Vaxart Trading Down 5.4%

OTCMKTS VXRT traded down $0.04 during trading on Friday, hitting $0.70. 691,277 shares of the company’s stock were exchanged, compared to its average volume of 433,090. The company has a market cap of $169.38 million, a PE ratio of 4.67 and a beta of 1.18. Vaxart has a fifty-two week low of $0.26 and a fifty-two week high of $0.84. The stock’s 50 day moving average price is $0.70 and its two-hundred day moving average price is $0.54.

Analysts Set New Price Targets

Separately, Wall Street Zen raised shares of Vaxart to a “buy” rating in a research report on Friday, January 23rd.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. acquired a new position in Vaxart during the first quarter worth about $31,000. Creative Planning bought a new stake in shares of Vaxart during the second quarter worth about $33,000. Invesco Ltd. increased its stake in shares of Vaxart by 93.1% in the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock valued at $60,000 after buying an additional 70,568 shares during the period. Raymond James Financial Inc. increased its stake in shares of Vaxart by 16.9% in the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 34,075 shares during the period. Finally, Jones Financial Companies Lllp increased its stake in shares of Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 478,111 shares during the period. Institutional investors and hedge funds own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.